Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes
EP. 1: Robert’s Journey With EGFR+ Metastatic NSCLC
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP The video segment profiles a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.
EP. 2: The Impact of Molecular Testing on Treatment Choices for NSCLC
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.
EP. 3: Overview of FLAURA and MARIPOSA-2 Clinical Trials
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.
EP. 4: Clinical Experience of Amivantamab in EGFR+ NSCLC Patients
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Kim shares his clinical experience with amivantamab in real-world practice for EGFR+ NSCLC, discussing both the benefits and challenges of incorporating it into treatment protocols.
EP. 5: Factors in Selecting Treatment Options for EGFR+ NSCLC
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Garon discusses his approach to selecting between available EGFR inhibitors for treating EGFR+ NSCLC.
EP. 6: Evaluating Treatment Options of EGFR Inhibitors
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.
EP. 7: Considerations for Second-Line Treatment Decisions in EGFR+ NSCLC: Sequencing Strategies and First-Line Choices
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.
EP. 8: Jason’s Journey with ALK+ Metatstatic NSCLC
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP EP. 9: Barriers and Challenges in Biomarker Testing for ALK+ NSCLC
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Garon discusses the factors that make a patient a strong candidate for ALK inhibitor therapy in ALK+ NSCLC, the importance of biomarker testing in guiding treatment selection, and his approach to testing along with challenges encountered, especially in community settings.
EP. 10: Overview of Efficacy of Lorlatinib in the Treatment of ALK+ NSCLC
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Kim provides an overview of the clinical evidence supporting lorlatinib as a first-line therapy for ALK+ metastatic NSCLC, focusing on the key efficacy outcomes from the phase 3 CROWN trial.
EP. 11: Overview of Current Treatment Landscape of ALK Inhibitors
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Garon describes the current treatment landscape for metastatic ALK+ NSCLC and explores alternative treatment options that could have been considered for these patients.
EP. 12: Clinical Experience of Lorlatinib ALK+ NSCLC Patients
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Kim discusses her experience with lorlatinib in real-world settings for ALK+ NSCLC, highlighting both the benefits and challenges of incorporating it into clinical practice.
EP. 13: Patient Factors Considered when Choosing Treatment Selection
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Garon explains his approach to choosing between different ALK inhibitors for ALK+ NSCLC, outlining the factors that guide his selection and when he might prefer alectinib, lorlatinib, or brigatinib.
EP. 14: Treatment Strategies in Disease Progression in ALK+ NSCLC
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Kim discusses her approach to selecting the next treatment for patients with ALK+ NSCLC who progress on lorlatinib, including the key factors she considers in making this decision.
EP. 15: Evaluating ALK Inhibitors in Treatment Sequencing and Testing
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Garon discusses the circumstances that might lead him to switch a patient with ALK+ NSCLC from another ALK inhibitor to lorlatinib.
EP. 16: Future Therapies for ALK+ Metastatic NSCLC
ByRajat Thawani, MD, MBBs ,Edward S. Kim, MD, MBA,Edward B. Garon, MD, MS ,Katherine Cunha, NP ,Blanca Ledezma, NP Dr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.
